Plain-English translation of NCT06926244 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is an observational study following real-world patients with IgA nephropathy, a common type of kidney disease. Researchers will review your medical records, kidney biopsy results, and lab work to identify which patients struggle to respond to available treatments—including newer kidney-protective medications like SGLT2 inhibitors and endothelin receptor antagonists. The goal is to understand what makes some people's disease resistant to treatment so doctors can eventually predict and prevent this outcome.
IgA nephropathy can progress very differently from person to person—some patients do well with standard treatment, while others develop persistent protein loss and kidney damage despite receiving the best available care. Doctors don't yet know how to predict who will respond to the new kidney-protective treatments becoming available in Europe, or how to identify patients early enough to change their course. This study aims to fill that gap.
You likely qualify if…
You likely don't qualify if…
You won't need to take any new medication or undergo extra procedures. Instead, researchers will review your existing kidney biopsy results, medical records, and laboratory tests to learn about your disease and how you've responded to treatments over time. This is a real-world observation study, so participation simply means allowing doctors to analyze your existing health information to help them understand patterns in kidney disease progression.
AI-generated summary from trial data · Aug 24, 2026 · Not medical advice
France